April 24, 2018: Global Study Published in JAMA Finds Treatment with Lonafarnib Extends Survival in Children with Progeria!

May 16, 2018: At JAMA Research's high heels, PRF and Eiger BioPharmaceuticals cooperated to seek Lonafarnib's FDA approval. This collaboration is the first treatment for Progeria. Once approved, children will get medication through prescription rather than clinical trials. Click here for details

Delivery of lonafanib is not approved by the US Food and Drug Administration (FDA). Therefore, it can be used only in specific clinical trials. The effect on humans in premature infants before clinical trials at FTI is unknown, but the effect on mice appears to be positive. In clinical trials in 2012, we found that we can improve weight gain and other early aging symptoms. Psychological development has not been adversely affected; in fact, intelligence is often average and above average. With regard to the signs of aging that seems to cause premature aging, the development of symptoms is comparable to aging, 8 to 10 times faster than usual. Regarding the aging properties that did not show early senescence, patients showed no tendency towards neurodegeneration or cancer. They also do not cause diseases generally associated with aging, such as cataract (caused by ultraviolet light) and osteoarthritis.

Researchers published cell culture and mouse model studies to support potential drug therapy in children of Progeria. Originally premature cellular features from the child have been developed for cancer farnesyl transferase inhibitors (FTI) in reverse of significant structural abnormalities in the cells. The clinician office of an internal rare disease (http://rarediseases.info.nih.gov/Default.aspx) has completed a comprehensive analysis of the natural history of premature aging of 15 children aged 15 years or younger did. 17 years to fully characterize the disease and gain insight into disease progression

Not a new paradigm, but we got some serious "more identical" things. According to a study published in the Journal of American Medical Association (JAMA) in 2014, the Food and Drug Administration (FDA) approved journal in 2002, the average of 72 cancer treatments prolongs the life of the poor moon. Two or three medicines approved between 2014 and 2016 will not benefit survival! In other words, the advantages are small, the toxicity is high, and the cost is still high. It is no wonder that we are losing war. Most anticancer drugs approved by the FDA are for the pursuit of marginal indications. They are not particularly useful, but they are particularly beneficial. This is the way you can hardly achieve the sense of growth of survival through a huge fee. If medicine was approved, much of the cost was absorbed. No matter how trivial the pursuit of ancillary indications is very beneficial, because they can survive only for a bit, they still pay the full price yet!